Although TP53 mutations were previously shown to be associated with lung cancer grade [4], few patient-matched DMRs were exclusive to low-stage (1/1A) or high-stage (3A/3B) tumors (10 and 9 DMRs, respectively; see Materials and methods). This evidence concerns the gene TP53 and lung cancer.